Timothy J. Kulis

Tim specializes in the representation of emerging growth companies throughout their lifecycles as well as venture capital investors. He maintains a broad practice including representing life sciences companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries as well as technology companies in the consumer internet, software, telecommunications and energy industries.

Tim’s practice focuses on general corporate counseling, venture capital financings, public offerings, public company representation and mergers and acquisitions. His practice spans the entire corporate lifecycle, from formation through liquidity. He regularly counsels companies in equity and debt financing transactions, including both early-stage and late-stage venture financings. He has advised issuers and underwriters in dozen of capital market transactions, including in several initial public offerings.

Tim’s representative company clients include Be Biopharma, Carbon Biosciences, DeepCure, GPR, Larkspur Biosciences, LightForce Orthodontics, Nubis Communications, Osmoses, Photys Therapeutics, RIGImmune, Solu Therapeutics and Well. Tim also represents a number of prominent venture capital funds and institutional investors in their financing activities. 

Prior to joining Gunderson Dettmer, Tim was a counsel in the corporate practice group at WilmerHale.